Subject: | |
From: | |
Reply To: | |
Date: | Wed, 10 Aug 2005 08:51:41 EDT |
Content-Type: | text/plain |
Parts/Attachments: |
|
|
I am looking at the article : "A controlled, randomized, double-blind trial
of prophylaxis against jaundice among breastfed infants" in the August issue
of Pediatrics. Two of the authors already hold a patent on the L-aspartic acid
intervention (Gourley and Kreamer) which can be viewed at
_http://www.warf.org/ipstatus/P01391US.PDF_ (http://www.warf.org/ipstatus/P01391US.PDF) . NIH
funding was also involved so the government holds part of this patent too. The
study was funded by 2 universities and Mead Johnson Nutritionals. There were
a whopping 64 babies in the study divided into 4 groups. The control group of
breastfed infants had their highest level of bilirubin, 8 mg/dl on day 4!
The study is notable for what it left out, such as breastfeeding management
guidelines, failure to disclose just what risk level the subjects were placed in
according to the Bhutani curve. Only 1 baby was actually in the highest risk
zone and the supplement was tested only on babies in the low to intermediate
risk zones. No comparison was made as to increasing the dose of
breastmilk.The authors state that 17 were in a risk zone above the low-risk zone. Their
results showed a 25% to 30% lower than control (no intervention) bilirubin
values. The authors also state that they have no competing interests!
Looks like another money-maker for the patent holders and Mead Johnson.
Marsha Walker, RN, IBCLC
Weston, MA
***********************************************
To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(R)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|